Home Edwards


New potential first-line treatment: transcatheter aortic valve implantation

Transaortic transcatheter aortic valve implantation (TAo-TAVI) is currently done only as a last resort, when implantation via the usual access routes (i.e. transapical or transfemoral) is impossible.

May 18, 2017

Cell injury process revealed

Mitochondria produced and destroyed in the heart during cardiac surgery could hold the key to quicker recovery, according to US researchers.

May 15, 2017

Thigh cells used to 'patch-up’ patients’ hearts

Patching a patient’s heart with their own cells could improve the symptoms of heart failure – a condition that affects around ­­­6 million people in the US.

May 15, 2017

Success for three-port endoscopic minimally invasive surgery

Researchers in Japan have demonstrated that three-port video-assisted thoracic surgery facilitates endoscopic minimally invasive mitral valve surgery.

May 15, 2017

Dabigatran better than warfarin at reducing bleeding after ablation

Patients anticoagulated with uninterrupted dabigatran have fewer bleeding complications after catheter ablation than those receiving uninterrupted warfarin, according to a recent clinical trial. The results could change the practice of electrophysiologists worldwide, and improve patient outcomes.

May 15, 2017

Seven variables predict probability of successful mitral valve repair

Assessing seven different variables before surgery can accurately predict the risk of an unsuccessful mitral valve repair. Researchers have devised a ‘scoring method’ using these variables which could assist cardiologists’ decisions when referring patients.

May 1, 2017

Thickened and shortened mitral leaflets predict aggravated mitral regurgitation

Patients with atrial fibrillation, a thickened anterior mitral leaflet and shortened posterior mitral leaflet may be at higher risk of aggravated mitral regurgitation after atrial septal defect closure. Identifying and carefully following up on these patients could improve post-surgical outcomes.

May 1, 2017

NOACs safe for most types of valvular heart disease

The safety and efficacy of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with valvular heart disease is similar to warfarin, according to a recent meta-analysis.

May 1, 2017